NasdaqGM:HELPPharmaceuticals
Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial
In June 2026, Helus Pharma reported that enrollment in Cybin’s APPROACH Phase 3 trial of HLP003 for adjunctive major depressive disorder surpassed 86%, advancing a program that holds FDA Breakthrough Therapy Designation and builds on earlier positive Phase 2 clinical outcomes.
This late-stage progress, alongside previously reported long-term efficacy signals, highlights how HLP003 could further shape Cybin’s pipeline profile if Phase 3 results are supportive.
We’ll now examine how this...